Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleUse of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study
Author(s)Faig-Martí J, Martínez-Catassús A
Journal, Volume, IssueJ Orthop Traumatol. 2017 Dec;18(4):451-455
Major outcome(s)Palmitoylethanolamide moderately effective in the treatment of carpal tunnel syndrome
IndicationAbstract
MedicationOther cannabinoids

BACKGROUND:
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that has shown anti-inflammatory activity and neuroprotection and has been used for the treatment of compressive syndromes. The aim of this study is to investigate the clinical and electrophysiological effects of conservative treatment with PEA in low to moderate carpal tunnel syndrome (CTS).

MATERIALS AND METHODS:
A prospective double-blinded randomized study was performed on 61 patients with a clinical and electrophysiologically confirmed diagnosis of low and moderate CTS. The patients were randomly assigned to two groups. Group N was given 300 mg of PEA twice a day over 60 days and Group P received a placebo with exactly the same appearance every 12 h for the same period. CTS was evaluated before and after treatment through clinical findings, Boston Carpal Tunnel Questionnaire, visual analog scale (VAS) and electrophysiological data. The results were evaluated with Student's t test and chi-squared test.

RESULTS:
No differences were observed in either group compared to the initial status regarding Durkan's test, Phalen's test, VAS and electrophysiological data after treatment. The Boston Questionnaire showed better results in both groups, with an improvement in only the symptom severity scale (SSS; p = 0.002809) for group P and improvement in the functional status scale (FSS; p = 0.03334) and SSS (p = 0.005) for group N.

CONCLUSIONS:
The results of this study suggest that treatment of CTS with PEA at a dose of 600 mg/day is not associated with an improvement of any clinical and electrophysiological parameters. However, we observed an improvement in the FSS in the Boston Questionnaire after treatment with PEA. Together with the results of other studies, we conclude that further studies of PEA in CTS at higher doses are necessary.

Route(s)
Dose(s)
Duration (days)
Participants
DesignControlled study
Type of publicationMedical journal
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]


up